NewAmsterdam Pharma has received a favorable opinion from the CHMP regarding its products Ubeslo and Evlarco, paving the way for potential EU marketing authorization.
The Committee for Medicinal Products for Human Use (CHMP) has issued a positive recommendation for NewAmsterdam Pharma's Ubeslo and Evlarco, which are based on obicetrapib. This decision is significant as it sets the stage for an official decision from the European Commission, expected in the second half of 2026.
Menarini, a key player in this development, has secured exclusive commercialization rights in Europe. NewAmsterdam Pharma stands to benefit from this partnership through tiered double-digit royalties and potential milestone payments totaling up to €833 million.
The positive opinion is supported by robust Phase 3 clinical trial data from the BROADWAY, BROOKLYN, and TANDEM studies, demonstrating impressive reductions in LDL-C levels—up to approximately 40% with monotherapy and around 50% when combined with ezetimibe. This strong efficacy profile underscores the potential of obicetrapib in managing cholesterol levels, which could have significant implications for cardiovascular health.
As the landscape for lipid-lowering therapies evolves, the anticipated approval of Ubeslo and Evlarco may enhance treatment options for patients and contribute to NewAmsterdam's growth in the competitive biotech sector.